Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

泰阁 - NMPA Drug Approval Details

Approvals/NMPA/Tigecycline for Injection

Approved

化学药品

Tigecycline for Injection

Pfizer Europe MA EEIG🇨🇳 National Medical Products Administration

Approval Date: Jan 5, 2026
Approval ID: 887dcYC1NdY
Company: Pfizer Europe MA EEIG
Type: 化学药品

Approval Details

Approval Id: 887dcYC1NdY
Approval Number: 国药准字HJ20160472
Generic Name: 注射用替加环素
Generic Name En: Tigecycline for Injection
Trade Name: 泰阁
Brand Name: 泰阁
Drug Type: 化学药品
Dosage Form: 注射剂
Strength: 50mg(按C₂₉H₃₉N₅O₈计)
Reg Date: 2026-01-05
Expired Date: 2031-01-04
Company Name: Pfizer Europe MA EEIG
Company Detail Path: /organization/pfizer-europe-ma-eeig

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Jan 5, 2026

Approval ID

887dcYC1NdY

Type

化学药品

Back to NMPA Approvals